On May 4, arGEN-X is presenting latest earnings. Wall Street analysts expect arGEN-X will release losses per share of €2.004. Watch arGEN-X stock price move in real-time ahead here. On May 4 ...

Kepler Capital analyst Christophe dombu maintained a Buy rating on arGEN X (0QW0 – Research Report) on September 25 and set a price target of €545.00. The company’s shares closed last Friday ...

Shire also agreed in return to pay arGEN-X €15 million ($20.4 million) upfront—consisting of €3 million ($4.08 million) cash and €12 million (about $16.35 million) in equity—as well as ...

Shire ( SHPGY) recently entered into an agreement with arGEN-X, a Netherlands-based privately-held biopharmaceutical company, to create novel treatments for rare genetic diseases. As per the terms ...

ROTTERDAM, The Netherlands, January 5, 2011 /PRNewswire/ -- arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE ...